dc.contributor.author | García Romero, Noemí | |
dc.contributor.author | Palacín Aliana, I. | |
dc.contributor.author | Madurga Lacalle, Rodrigo | |
dc.contributor.author | Carrión Navarro, Josefa | |
dc.contributor.author | Esteban Rubio, S. | |
dc.contributor.author | Jiménez, B. | |
dc.contributor.author | Collazo, A. | |
dc.contributor.author | Pérez Rodríguez, F. | |
dc.contributor.author | Ortiz de Mendivil, A. | |
dc.contributor.author | Fernández Carballal, C. | |
dc.contributor.author | García Duque, s. | |
dc.contributor.author | Diamantopoulos-Fernández, J. | |
dc.contributor.author | Belda Iniesta, C. | |
dc.contributor.author | Prat Acín, R. | |
dc.contributor.author | Sánchez Gómez, P. | |
dc.contributor.author | Calvo, E. | |
dc.contributor.author | Ayuso Sacido, Ángel | |
dc.date.accessioned | 2020-10-22T08:28:08Z | |
dc.date.available | 2020-10-22T08:28:08Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1741-7015 | spa |
dc.identifier.uri | http://hdl.handle.net/10641/2022 | |
dc.description.abstract | Background
Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival.
Methods
We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment.
Results
We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance.
Conclusions
Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment. | spa |
dc.language.iso | eng | spa |
dc.publisher | BMC Medicine | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | VEGFA | spa |
dc.subject | Angiogenesis | spa |
dc.subject | Bevacizumab | spa |
dc.subject | Glioblastoma | spa |
dc.subject | Neovasculogenesis | spa |
dc.title | Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | AM | spa |
dc.rights.accessRights | open access | spa |
dc.description.extent | 1360 KB | spa |
dc.identifier.doi | 10.1186/s12916-020-01610-0 | spa |
dc.relation.publisherversion | https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01610-0 | spa |